Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

杜瓦卢马布 医学 胆道癌 吉西他滨 内科学 顺铂 胆道 肿瘤科 真实世界数据 胰腺癌 胃肠病学 癌症 化疗 计算机科学 数据科学 无容量 免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Sara Lonardi,Monica Niger,Daniele Lavacchi,Tiziana Pressiani,Jessica Lucchetti,Guido Giordano,Andrea Pretta,Emiliano Tamburini,Chiara Pirrone,Ilario Giovanni Rapposelli,Anna Diana,Erika Martinelli,Ingrid Garajovà,Francesca Simionato,Marta Schirripa,Vincenzo Formica,Caterina Vivaldi,Enrico Caliman,Mario Domenico Rizzato,Valentina Zanuso,Federico Nichetti,Lorenzo Angotti,Matteo Landriscina,Mario Scartozzi,Matteo Ramundo,Alessandro Pastorino,Bruno Daniele,Noemi Cornara,Mara Persano,Eleonora Gusmaroli,Riccardo Cerantola,Francesca Salani,Francesca Ratti,Luca Aldrighetti,Stefano Cascinu,Lorenza Rimassa,Lorenzo Antonuzzo,Andrea Casadei‐Gardini
出处
期刊:Liver International [Wiley]
卷期号:43 (8): 1803-1812 被引量:43
标识
DOI:10.1111/liv.15641
摘要

Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer. The present study investigated the efficacy and safety of this new standard treatment in a real‐world setting. Methods The analysed population included patients with unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract treated with durvalumab in combination with gemcitabine and cisplatin at 17 Italian centres. The primary endpoint of the study was progression‐free survival (PFS), whereas secondary endpoints included overall survival (OS), overall response rate (ORR) and safety. Unadjusted and adjusted hazard ratios (HRs) by baseline characteristics were calculated using the Cox proportional hazards model. Results From February 2022 to November 2022, 145 patients were enrolled. After a median follow‐up of 8.5 months (95% CI: 7.9–13.6), the median PFS was 8.9 months (95% CI: 7.4–11.7). Median OS was 12.9 months (95% CI: 10.9–12.9). The investigator‐assessed confirmed ORR was 34.5%, and the disease control rate was 87.6%. Any grade adverse events (AEs) occurred in 137 patients (94.5%). Grades 3–4 AEs occurred in 51 patients (35.2%). The rate of immune‐mediated AEs (imAEs) was 22.7%. Grades 3–4 imAEs occurred in 2.1% of the patients. In univariate analysis, non‐viral aetiology, ECOG PS >0 and NLR ≥3 correlated with shorter PFS. Conclusion The results reported in this first real‐world analysis mostly confirmed the results achieved in the TOPAZ‐1 trial in terms of PFS, ORR and safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
请叫我风吹麦浪应助rain采纳,获得30
1秒前
123完成签到,获得积分10
1秒前
xx完成签到,获得积分10
1秒前
ZD完成签到 ,获得积分10
2秒前
科研通AI5应助Rui采纳,获得10
2秒前
yyj发布了新的文献求助10
2秒前
斯文静曼发布了新的文献求助10
2秒前
k7应助快乐滑板采纳,获得10
4秒前
假行僧发布了新的文献求助10
4秒前
4秒前
Wyoou完成签到,获得积分10
5秒前
5秒前
5秒前
故意的傲玉应助lll采纳,获得10
5秒前
6秒前
请叫我风吹麦浪应助lm采纳,获得10
6秒前
6秒前
6秒前
7秒前
科研通AI5应助水獭采纳,获得10
8秒前
8秒前
8秒前
研友_nv2r4n发布了新的文献求助10
9秒前
喵叽发布了新的文献求助10
9秒前
槐夏完成签到,获得积分10
9秒前
10秒前
科研通AI5应助su采纳,获得10
10秒前
10秒前
科目三应助MJQ采纳,获得30
10秒前
10秒前
慕子发布了新的文献求助20
11秒前
lumangxiaozi完成签到,获得积分10
11秒前
积极的凌波完成签到,获得积分10
11秒前
xiaxiao应助小小酥采纳,获得100
11秒前
523完成签到,获得积分10
11秒前
11秒前
12秒前
13秒前
13秒前
Hupoo发布了新的文献求助10
13秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762